Skip to content
lifestyle.cleanweb.co
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Artelo Biosciences
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
August 17, 2026
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
August 13, 2026
Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma
August 10, 2026
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
May 14, 2026
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
May 4, 2026
Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
May 3, 2026
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
May 2, 2026
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
May 1, 2026
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
May 1, 2026
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
May 1, 2026
1
2
Next Page
→